Address
Excalibur Fund Managers Ltd
Berkeley Square
Berkeley Square House
London
W1J 6BD
United Kingdom
Phone
Email
KANDO id: 32746
Funds managed
| Fund | Type | Vintage | Currency | Committed capital |
|---|---|---|---|---|
| Merlin Biosciences Fund III LP | Venture | 2003 | EUR | 139,000,000 |
Funding rounds
Investment preferences
Investment activity status
Not investing
Selected investments
Displaying 1 - 25 of 35| Company | Profile | Country | Funding | ||
|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Amura Ltd | A structure-based drug discovery business specialising in diseases such as osteoporosis, osteoarthritis, bone metasta. Secondary sale in February 2005 | N/A | ||
|
|
Ardana PLC | Drugs for reproductive disorders and hormone sensitive cancers. IPO in March 2005. | N/A | ||
|
|
Ark Therapeutics Group PLC | Gene-based drugs for vascular and circulatory diseases and cancer. IPO in March 2004. | N/A | ||
|
|
Biovertis AG | Hospital-acquired infections; respiratory tract infections; urinary tract infections. Acquired Morphochem AG in March 2006. | N/A | ||
|
|
Biowisdom Ltd | Knowledge management software for drug development. | N/A | ||
|
|
Cambridge Biotechnology Ltd | Small molecule drugs for pain and obesity. Aquired by Biovitrum AB in April 2005. | N/A | ||
|
|
Cyclacel Pharmaceutical Inc | Cell cycle control drugs for cancer. IPO in January 2006. | N/A | ||
|
|
De Novo Pharmaceuticals Ltd | A world leader in in-silico structure-based drug design, de novo drug design. | N/A | ||
|
|
Decon Sciences Ltd | Decontamination services provider | N/A | ||
|
|
DestinationSkin Ltd | Skin treatment and hair removal. | N/A | ||
|
Emergent BioSolutions Inc | Research, development and manufacture of novel vaccines and related products IPO in November 2006. Fully disposed. | N/A | ||
|
|
Energist Ltd | Manufactures and markets lasers and light-based systems for hair removal and aesthetic skin treatments, serving both the medical and beauty sectors. | N/A | ||
|
|
EpiCept Inc | Topical pain management. IPO in January 2006. | N/A | ||
|
|
Intercytex Group PLC | A UK Regenerative Medicine Company product and services. IPO in February 2006. Presently known as Regenerative Medicine Assets Ltd. | N/A | ||
|
|
KinderTec Ltd | Paediatric consumer healthcare products. Trade sale in December 2005. | N/A | ||
|
|
Lab21 Ltd | N/A | |||
|
|
LiDCO Group PLC | Researches, develops, manufactures and sells innovative medical devices. IPO in June 2004. | N/A | ||
|
|
Microscience Investments Ltd | Vaccines for typhoid, travellers’ illnesses and hepatitis B Merged with NASDAQ listed Emergent Biosolutions Inc in July 2005. | N/A | ||
|
|
Neurotech Pharmaceuticals Inc (Neurotech Inc) | Cell-based drugs for diseases of the eye. | N/A | ||
|
|
Noxxon Pharma AG | Mirror image oligonucleotide drugs. | N/A | ||
|
|
Onyvax Ltd | Whole-cell allogenic vaccines for cancer. Acquired by VaxOnco Inc. | N/A | ||
|
|
PanTherix Ltd | A start-up biotech specializing in antibiotic target validation and drug discovery. | N/A | ||
|
|
Paradigm Therapeutics Ltd | Drug discovery platform company Acquired by Takeda Pharmaceutical Company Ltd in December 2004. | N/A | ||
|
|
PIramed Pharma Ltd | Oncology Therapeutics. Acquired by Roche in April 2008. | N/A | ||
|
|
Plethora Solutions Holdings PLC | Discovering and developing urological products. IPO in March 2005. | N/A |
